Education
About Us
Working with TipRanks
Follow Us
Algernon Pharmaceuticals (TSE:AGN)
:AGN
Total Valuation
Algernon Pharmaceuticals has a market cap or net worth of C$2.56M. The enterprise value is C$2.22M.
Market CapC$2.56M
Enterprise ValueC$2.22M
Share Statistics
Algernon Pharmaceuticals has 46,499,270 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding46,499,270
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Algernon Pharmaceuticals’s return on equity (ROE) is -0.64 and return on invested capital (ROIC) is -63.73%.
Return on Equity (ROE)-0.64
Return on Assets (ROA)-0.35
Return on Invested Capital (ROIC)-63.73%
Return on Capital Employed (ROCE)-0.64
Revenue Per Employee0.00
Profits Per Employee-1.72M
Employee Count1
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Algernon Pharmaceuticals is ―. Algernon Pharmaceuticals’s PEG ratio is -0.00912.
PE Ratio―
PS Ratio0.00
PB Ratio0.77
Price to Fair Value0.77
Price to FCF-1.78
Price to Operating Cash Flow-1.78
PEG Ratio-0.00912
Income Statement
In the last 12 months, Algernon Pharmaceuticals had revenue of 0.00 and earned -1.72M in profits. Earnings per share was -0.06.
Revenue0.00
Gross Profit-54.69K
Operating Income-1.72M
Pretax Income-1.72M
Net Income-1.72M
EBITDA-1.66M
Earnings Per Share (EPS)-0.06
Cash Flow
In the last 12 months, operating cash flow was -1.16M and capital expenditures -3.00, giving a free cash flow of -1.16M billion.
Operating Cash Flow-1.16M
Free Cash Flow-1.16M
Free Cash Flow per Share-0.02
Dividends & Yields
Algernon Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.25
52-Week Price Change-31.25%
50-Day Moving Average0.08
200-Day Moving Average0.08
Relative Strength Index (RSI)20.99
Average Volume (3m)13.80K
Important Dates
Algernon Pharmaceuticals upcoming earnings date is Feb 3, 2026, TBA (Confirmed).
Last Earnings DateDec 30, 2025
Next Earnings DateFeb 3, 2026
Ex-Dividend Date―
Financial Position
Algernon Pharmaceuticals as a current ratio of 0.25, with Debt / Equity ratio of 0.00%
Current Ratio0.25
Quick Ratio0.25
Debt to Market Cap0.00
Net Debt to EBITDA0.11
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Algernon Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Algernon Pharmaceuticals EV to EBITDA ratio is -1.14, with an EV/FCF ratio of -1.63.
EV to Sales0.00
EV to EBITDA-1.14
EV to Free Cash Flow-1.63
EV to Operating Cash Flow-1.63
Balance Sheet
Algernon Pharmaceuticals has C$176.50K in cash and marketable securities with C$0.00 in debt, giving a net cash position of C$176.50K billion.
Cash & Marketable SecuritiesC$176.50K
Total DebtC$0.00
Net CashC$176.50K
Net Cash Per Share<C$0.01
Tangible Book Value Per Share-C$0.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Algernon Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast64.77%